LKC Technologies

LKC Technologies, **headquartered** in the United States, has been **transforming the world of visual electrophysiology** since **1976**. With a focus on the **Health Care** and **Manufacturing** industries, the company has been a pioneer in making functional eye testing practical for clinicians. Their handheld, portable RETeval® ERG/VEP device has been instrumental in aiding the diagnosis and management of ischemic conditions such as diabetic retinopathy, optic nerve conditions, and retinal dystrophies. Having recently secured a **Private Equity Round investment** on **12 June 2023**, with **DW Healthcare Partners** as the investors, LKC Technologies has demonstrated its potential for growth and innovation in the health technology sector. The company's commitment to providing objective results without corneal contact shows promise for helping clinicians effectively manage various eye conditions. With a strong track record that spans over **45 years**, LKC Technologies continues to show promise in creating impactful solutions for the healthcare industry. As the demand for efficient and practical eye testing solutions continues to grow, LKC Technologies is well-positioned to make a significant impact in the field of visual electrophysiology.